Thursday, September 24, 2026
ExploreSearch
Via News
Via News Knowledge File

Eli Lilly and Company

organization80% conf.·synced Sep 23, 2026

Pharmaceutical company with gene therapy licensing deal with REGENXBIO

60
sourced metrics
1279
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
1123.00USD
Sep 10, 2026reference only
Price 52 Week High
1280.34USD
Sep 10, 2026reference only
Market Cap
1057143983995USD
Sep 10, 2026reference only
Price 52 Week Low
714.59USD
Sep 10, 2026reference only
Stock Return Ytd
3.9%
Sep 10, 2026reference only
Shares Outstanding
941357065.0shares
Aug 3, 2026reference only
Net Income
7095000000.0USD
Jun 30, 2026reference only
Eps
7.94USD_per_share
Jun 30, 2026reference only
Revenue
22974000000.0USD
Jun 30, 2026reference only
Cash
8950000000.0USD
Jun 30, 2026reference only
Total Assets
142283000000.0USD
Jun 30, 2026reference only
Stockholders Equity
33879000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
3268000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
5333000000.0USD
Mar 31, 2026reference only

Stated objectives

Obtain U.S. regulatory approval for Inluriyo in combination with abemaciclib for ESR1-mutated MBC

source
stated

Advance LY4064809/STX-478 from Phase 1/2 to Phase 3 trial for PIK3CA-mutant HR+, HER2- advanced breast cancer

source
stated

Demonstrate overall survival benefit, progression-free survival, and time to chemotherapy improvements in EMBER-3 trial for ESR1-mutated breast cancer

source
stated

Show sustained IDFS/DRFS improvements and OS prolongation in monarchE trial across nodal status subgroups

source
stated

Translate biologic conviction into meaningful progress by addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K

source
stated

Demonstrate non-inferiority of pirtobrutinib versus ibrutinib on overall response rate in CLL/SLL patients

source
target: non-inferiority on ORR stated

Complete formal PFS analysis testing for superiority of pirtobrutinib

source
target: superiority on PFS stated

Verify and describe clinical benefit of Jaypirca in confirmatory trials to maintain accelerated approval status

source
target: clinical benefit verification stated

Demonstrate pirtobrutinib's potential role across treatment settings and B-cell malignancies through development program

source
stated

Receive regulatory approvals for pirtobrutinib in earlier disease settings to expand treatment options for patients

source
target: regulatory approval by 2026-01-01 00:00:00stated

Relationship graph · 1279 connections

Developed by
512
Competes with
198
Employs
82
Covered by
57
acquired by
54
regulates
45
headquartered in
43
located in
27
board member of
Dave Ricks

Via News coverage

Novo Nordisk Surges 24.9%, Exits Parkinson's Unit as NVIDIA's BioNeMo Becomes Global Pharma AI Standard
June 27, 2026
NVIDIA's BioNeMo Becomes Global Drug Discovery Infrastructure as Pharma Outsources R&D to AI Platforms
June 19, 2026
NVIDIA Locks Eli Lilly and Thermo Fisher Into AI Drug Discovery Platform as Pharma R&D Goes Structural
June 1, 2026
NVIDIA Locks Lilly and Thermo Fisher Into BioNeMo as Global Drug Discovery Platform Race Intensifies
May 27, 2026
NVIDIA's BioNeMo Becomes Global Drug Discovery's Default AI Infrastructure as Big Pharma Cedes Biology to Specialists
May 21, 2026
NVIDIA's BioNeMo Becomes Global Drug Discovery Infrastructure as Eli Lilly and Thermo Fisher Join Platform
May 16, 2026
NVIDIA Locks In Eli Lilly and Thermo Fisher as BioNeMo Becomes Global Pharma AI Backbone
May 1, 2026
NVIDIA BioNeMo Platform Secures Partnerships with Eli Lilly, Thermo Fisher for AI Drug Discovery
April 21, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com